Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rise of the patient affairs officer; Sanofi makes appointment

This article was originally published in Scrip

Executive Summary

Following the growing trend of pharmaceutical companies embracing patient-centric business models, Sanofi has appointed Dr Anne C Beal chief of patient affairs. The French pharma is the first of the top ten biopharmaceutical companies to create space for such a position, according to Pascale Witz executive vice-president of global and strategic development.

You may also be interested in...



UCB's Head of Corporate Strategy On Deals, Divestments And Sector-Wide Challenges

UCB's recently appointed head of corporate strategy and business development Alexander Moscho, who joined the company in October 2017, talks to Scrip about UCB's future growth, internal R&D pipeline and potential for significant deal-making in 2018.

Patient Engagement: How Soon Do You Start?

Julie Adrian, European managing director of inVentiv Health Communications, outlines the greatest barriers preventing companies from engaging patients earlier in drug development and highlights the greatest benefits on offer to those that can successfully implement patient-centric drug discovery models.

Femtech Presents Enticing Market Opportunity

A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.

Related Companies

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel